No abstract

Irinotecan plus cisplatin is an effective treatment for metastatic small-cell lung cancer.

The four regimens have similar efficacy and different toxicity profiles, and they can be used to treat advanced NSCLC patients.

Noninferiority in overall survival between gefitinib and docetaxel was not demonstrated according to predefined criteria; however, there was no statistically significant difference in overall survival. Secondary end points showed similar or superior efficacy for gefitinib compared with docetaxel. Gefitinib remains an effective treatment option for previously treated Japanese patients with NSCLC.